Benefits include histopathologic downstaging, fewer incomplete resections, and better two-year disease control<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Feb. 1, 2023 (HealthDay News) — Six weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy is safe and effective for operable colon cancer, without increasing perioperative morbidity, according to a study published online Jan. 19 in the Journal of Clinical Oncology<\/em>.<\/p>\n Dion Morton, M.D., from University Hospital Birmingham in the United Kingdom, and colleagues randomly assigned patients with radiologically staged T3-4, N0-2, M0 colon cancer (2:1) to six weeks oxaliplatin-fluoropyrimidine preoperatively plus 18 weeks postoperatively (neoadjuvant chemotherapy [NAC] group; 699 patients) or 24 weeks postoperatively (control group; 354 patients). Additionally, patients with RAS<\/em>-wildtype tumors could also be randomly assigned (1:1) to receive panitumumab or not during NAC.<\/p>\n The researchers found that NAC was associated with marked T and N downstaging and histologic tumor regression. Furthermore, resection in NAC patients was more often histopathologically complete: 94 versus 89 percent. Compared with controls, fewer NAC patients had residual or recurrent disease within two years: 16.9 versus 21.5 percent (rate ratio, 0.72). There was a strong correlation between tumor regression and freedom from recurrence. There was no additional benefit observed from panitumumab with NAC, and little benefit from NAC was seen in mismatch repair-deficient tumors.<\/p>\n “Six weeks of NAC should be considered as a treatment option for locally advanced colon cancer,” the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text<\/a><\/p>\n